Experts discuss the latest advancements in HER2 testing and treatment strategies for non-small cell lung cancer, enhancing clinical practice and patient outcomes.
Back
Advancements in the Management of HER2-Mutated Non-Small Cell Lung Cancer
This OncLive Insights program features Drs. Sandip Patel and Jonathan Riess in an in-depth discussion on current and emerging strategies for managing HER2-mutated non-small cell lung cancer (NSCLC). The experts review the evolving diagnostic landscape, emphasizing the importance of comprehensive molecular testing, both tissue and plasma, to identify HER2 mutations and HER2 IHC 3+ overexpression. They examine the clinical integration of targeted therapies including trastuzumab deruxtecan (T-DXd), zongertinib, and the recently reported sevabertinib, highlighting their efficacy, safety profiles, and roles across lines of therapy. Key challenges are addressed, such as CNS metastases, sequencing uncertainty, toxicity monitoring, and the need for resistance-based treatment strategies. The discussion concludes with a forward-looking perspective on next-generation HER2 inhibitors, ADC development, CNS-penetrant agents, and opportunities to advance care through clinical trials and real-world evidence.
Advancements in the Management of HER2-Mutated Non-Small Cell Lung Cancer
Episodes
All
All
Explore the latest advancements in HER2 testing and treatment strategies for non-small cell lung cancer in this insightful discussion.
Experts discuss the importance of HER2 IHC testing and tissue management in cancer treatment, emphasizing its role in personalized therapy.
Explore the latest advancements in HER2 testing and treatment strategies for non-small cell lung cancer, enhancing patient outcomes and options.
Explore the latest insights on sevobertnib and zonertinib in treating HER2-mutated non-small-cell lung cancer, focusing on efficacy and toxicity differences.
Explore the latest insights on sevobertnib and zonertinib in treating HER2-mutated non-small-cell lung cancer, focusing on efficacy and toxicity differences.
Explore the latest strategies in treating HER2-mutated non-small cell lung cancer with antibody-drug conjugates and targeted therapies.
Experts discuss the evolving treatment landscape for HER2-mutated non-small cell lung cancer, focusing on trastuzumab deruxtecan and zonertinib efficacy.
Experts discuss the evolving landscape of HER2-targeted therapies in non-small cell lung cancer, emphasizing the need for more data and innovative treatments.
Advertisement
Advertisement
Trending on OncLive
1
Phase 3 eVOLVE-Lung02 Trial of First-Line Volrustomig Is Discontinued in First-Line Metastatic NSCLC
2
T-DXd Improves PFS in First-Line HER2-Mutant NSCLC
3
FDA Grants Fast Track Designation to Sapanisertib and Serabelisib Plus Paclitaxel in Advanced Endometrial Cancer
4
Dr Viansone on ADC Sequencing in Metastatic HER2+ Breast Cancer
5